GlaxoSmithKline Gains Antibody for Type I Diabetes
By Business Review Editor
Pharma Deals Review: Vol 2007 Issue 90 (Table of Contents)
Published: 7 Dec-2007
DOI: 10.3833/pdr.v2007.i90.249 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
GlaxoSmithKline and Tolerx entered into license agreement for Tolerx’s otelixizumab (TRX4) monoclonal antibody for treating type I diabetes...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS